| Twist1 is a key regulator of cancer-associated fibroblasts KW Lee, SY Yeo, CO Sung, SH Kim Cancer research 75 (1), 73-85, 2015 | 153 | 2015 |
| The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma SY Ha, SY Yeo, Y Xuan, SH Kim PloS one 9 (6), e99955, 2014 | 145 | 2014 |
| A positive feedback loop bi-stably activates fibroblasts SY Yeo, KW Lee, D Shin, S An, KH Cho, SH Kim Nature communications 9 (1), 3016, 2018 | 107 | 2018 |
| Tenascin-C, a prognostic determinant of esophageal squamous cell carcinoma ZT Yang, SY Yeo, YX Yin, ZH Lin, HM Lee, YH Xuan, Y Cui, SH Kim PLoS One 11 (1), e0145807, 2016 | 70 | 2016 |
| PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression KW Lee, SY Yeo, JR Gong, OJ Koo, I Sohn, WY Lee, HC Kim, SH Yun, ... Nature Communications 13 (1), 2793, 2022 | 40 | 2022 |
| Ubiquitin-specific protease 21 promotes colorectal cancer metastasis by acting as a Fra-1 deubiquitinase SI Yun, HK Hong, SY Yeo, SH Kim, YB Cho, KK Kim Cancers 12 (1), 207, 2020 | 36 | 2020 |
| Twist1 is highly expressed in cancer-associated fibroblasts of esophageal squamous cell carcinoma with a prognostic significance SY Yeo, SY Ha, KW Lee, Y Cui, ZT Yang, YH Xuan, SH Kim Oncotarget 8 (39), 65265, 2017 | 36 | 2017 |
| Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis HM Lee, E Lee, SY Yeo, S Shin, HK Park, DH Nam, SH Kim Investigational New Drugs 36, 545-560, 2018 | 17 | 2018 |
| ZNF282 (Zinc finger protein 282), a novel E2F1 co-activator, promotes esophageal squamous cell carcinoma SY Yeo, SY Ha, EJ Yu, KW Lee, JH Kim, SH Kim Oncotarget 5 (23), 12260, 2014 | 15 | 2014 |
| New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts E Lee, SY Yeo, KW Lee, JA Lee, KK Kim, SH Kim Scientific Reports 10 (1), 7058, 2020 | 6 | 2020 |
| Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma S Choi, KW Lee, HH Koh, S Park, SY Yeo, JW Joh, MS Choi, SH Kim, ... Journal of Cancer Research and Clinical Oncology 147 (12), 3517-3534, 2021 | 4 | 2021 |
| Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma SY Ha, SY Yeo, KW Lee, SH Kim Journal of Cancer Research and Clinical Oncology 147, 423-433, 2021 | 1 | 2021 |
| Abstract LB320: Runx2 as a key transcription factor regulating contractility and extracellular matrix remodeling in abnormally activated fibroblasts: Implications for … KW Lee, I Sohn, SH Kim, SY Yeo Cancer Research 84 (7_Supplement), LB320-LB320, 2024 | | 2024 |
| Abstract LB321: Identification of a novel mode of action and scaffold for modulation of cancer-associated fibroblast through Chip-seq analysis SY Yeo, M Farh, IS Sohn, SH Kim, KW Lee Cancer Research 84 (7_Supplement), LB321-LB321, 2024 | | 2024 |
| Abstract LB322: ARC2-001, a CAF-targeting drug exhibits strong anticancer effect in in vivo setting SY Yeo, M Farh, IS Sohn, SH Kim, KW Lee Cancer Research 84 (7_Supplement), LB322-LB322, 2024 | | 2024 |
| Abstract LB283: ARC2-001 inhibits cancer-associated fibroblast-dependent cancer stem cell populations by disrupting cancer-stroma interactions KW Lee, SY Yeo, IS Sohn, SH Kim Cancer Research 83 (8_Supplement), LB283-LB283, 2023 | | 2023 |
| Abstract LB282: RUNX2 is a master transcription factor that determines the identity of cancer-associated fibroblast subtypes with abnormal activation in the tumor microenvironment SY Yeo, KW Lee, I Sohn, SH Kim Cancer Research 83 (8_Supplement), LB282-LB282, 2023 | | 2023 |
seok-hyung kimSungkyunkwan University, college of medicine, Samsung medical center在 skku.edu 的电子邮件经过验证
